The promise of mRNA vaccines: a biotech and industrial perspective
Coalition for Epidemic Preparedness Innovations · Sanofi (United States) · +2 more institutions
Abstract
MRNA technologies have the potential to transform areas of medicine, including the prophylaxis of infectious diseases. The advantages for vaccines range from the acceleration of immunogen discovery to rapid response and multiple disease target manufacturing. A greater understanding of quality attributes that dictate translation efficiency, as well as a comprehensive appreciation of the importance of mRNA delivery, are influencing a new era of investment in development activities. The application of translational sciences and growing early-phase clinical experience continue to inform candidate vaccine selection. Here we review the state of the art for the prevention of infectious diseases by using mRNA and…
Citation impact
- FWCI
- 29.17
- Percentile
- 100%
- References
- 68
Authors
5- NANicholas A. C. JacksonCorresponding
Coalition for Epidemic Preparedness Innovations
- KEKent E. Kester
Sanofi (United States), Drug Discovery Laboratory (Norway)
- DRDanilo R. Casimiro
Sanofi (United States), Drug Discovery Laboratory (Norway)
- SGSanjay Gurunathan
Sanofi (United States), Drug Discovery Laboratory (Norway)
- FDFrank DeRosa
Translate Bio (United States)
Topics & keywords
- Immunogen
- Biotechnology
- Infectious disease (medical specialty)
- Translational medicine
- Business
- Disease
- Medicine
- Biology
- Industry, innovation and infrastructure